NanoViricides, Inc. (NYSE American: NNVC) announced that the U.S. FDA has granted Orphan Drug Designation to its clinical-stage antiviral drug NV-387 for the treatment of measles. This designation provides potential incentives including tax credits, fee exemptions, and market exclusivity upon approval, which the company believes will support the regulatory advancement of NV-387. Measles, a highly contagious viral disease, has seen a resurgence globally, with outbreaks increasing due to declining vaccination rates. The World Health Organization reported a 79% rise in measles cases in 2023 compared to the previous year, highlighting the urgent need for effective treatments.
NV-387 is a broad-spectrum antiviral candidate that has demonstrated in vivo activity against measles in animal models. Beyond measles, NV-387 has shown efficacy in animal models for other viral threats including monkeypox (MPox), smallpox, and respiratory viruses such as RSV, COVID-19, and influenza. The drug is designed to mimic host cell receptors, binding to viruses and neutralizing them before they can infect cells. This mechanism gives NV-387 the potential to treat a wide range of enveloped viruses, making it a promising candidate in the fight against emerging viral diseases.
The Orphan Drug Designation is a significant milestone for NanoViricides, as it can accelerate the development process through FDA guidance and potential financial benefits. The company plans to leverage this designation to advance NV-387 into Phase II human clinical trials, following the successful completion of a Phase I trial in healthy volunteers that reported no adverse events. The Phase I trial demonstrated safety and tolerability, paving the way for efficacy studies in infected patients.
NanoViricides is focused on addressing the global health threat posed by measles, which can cause severe complications such as pneumonia, encephalitis, and death, particularly in children and immunocompromised individuals. Current treatment options are limited to supportive care and vitamin A supplementation, with no specific antiviral therapy approved. NV-387 could fill this gap, providing a direct-acting antiviral to reduce severity and transmission.
The company is also developing other drug candidates, including NV-HHV-1 for herpesvirus infections. However, NV-387 remains the lead candidate, with a broad-spectrum profile that positions it as a potential first-line treatment for multiple viral infections. The global antiviral market is projected to grow significantly, driven by the need for effective therapies against emerging and re-emerging viruses.
For more information, visit the company's newsroom at https://ibn.fm/NNVC.
